Rapport Therapeutics, Inc. 4

Chief Development Officer Yeleswaram Krishnaswamy sold 404 shares of Rapport Therapeutics, Inc. common stock at $49.90 per share under a Rule 10b5-1 plan.

On August 19, 2026, Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics, Inc., sold 404 shares of the company’s common stock at a price of $49.90 per share, for total proceeds of approximately $20,160, under a pre-arranged Rule 10b5-1 trading plan, leaving him with beneficial ownership of 246,022 shares following the transaction.

Filing Facts

CIK

2012593

Ticker

RAPP

Form

4

Source Type

fda

Accession

0001193125-26-359189

Alert Tier

5